PEP 020

Drug Profile

PEP 020

Alternative Names: DPT PEP3; PEP-020

Latest Information Update: 15 Nov 2016

Price : $50

At a glance

  • Originator PEP-Therapy
  • Class Peptides
  • Mechanism of Action Protein-protein interaction inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 Nov 2016 PEP-Therapy has patent protection for its Cell Penetrating & Interfering Peptides technology (PEP-therapy website, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top